Drug class
Synthetic polymer immunomodulator (polyoxidonium); mechanism-based class not established in major regulatory references
Mechanism of action
Proposed to modulate innate immune responses and phagocyte activity; a defined molecular target and mechanism of clinical benefit are not established in widely recognised FDA/EMA product labels.
General use cases
- Used in selected countries for adjunctive prevention or treatment of recurrent infections under local product authorisations; there is no general FDA or EMA-authorised therapeutic indication to assign
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
